Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2025-10-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
投资者关系管理制度(2025年10月）
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System'. It outlines the company's policies, principles, and organizational structure for managing investor relations, including communication with investors, disclosure obligations, and governance related to investor relations. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The document is a governance-related policy document detailing internal rules and procedures for investor relations management. Therefore, it fits best under Governance Information (CGR). The document length is 4601 characters, which is sufficient for a detailed policy document, not a brief announcement or certification.
2025-10-28 Chinese
董事、高级管理人员所持公司股份及其变动管理制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled as a management system for the holdings and changes of shares by directors and senior management of the company. It details rules and regulations governing the shareholding, trading restrictions, reporting obligations, and penalties related to directors and senior management. There is no financial data, no report of financial results, no announcement of voting results, no legal proceeding update, no merger or acquisition information, and no presentation or transcript. The document is a governance-related internal regulation concerning board and management share dealings. This fits best under the category of Governance Information (CGR), which covers internal rules and governance practices related to board and management.
2025-10-28 Chinese
关于2025年前三季度计提资产减值准备及核销资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 美康生物科技股份有限公司 regarding the company's asset impairment provisions and asset write-offs for the first three quarters of 2025. It details the amounts of impairment provisions, the reasons for these provisions, the accounting standards applied, and the impact on the company's financial results. The document is relatively short (3000 characters) and serves as a disclosure or announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). Instead, it is a regulatory announcement about specific accounting actions taken during the period. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-28 Chinese
关于调整组织架构并修订《公司章程》、修订及制定公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from 美康生物科技股份有限公司 regarding adjustments to the company's organizational structure, revisions to the company's articles of association (公司章程), and governance system updates. It includes extensive legal and regulatory references, detailed changes to governance rules, board composition, shareholder rights, and other corporate governance matters. The document is lengthy (15,000 characters) and contains substantive content about governance changes rather than just an announcement of a report or a brief notice. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement of voting results or a proxy solicitation. The focus on governance structure, board changes, and company bylaws aligns with the category of Governance Information (CGR). Therefore, the document is best classified as Governance Information (CGR).
2025-10-28 Chinese
关联交易管理办法(2025年10月）
Governance Information Classification · 95% confidence The document is titled "关联交易管理办法" which translates to "Related Party Transaction Management Measures". It is a detailed internal policy document outlining the principles, definitions, approval procedures, pricing, and disclosure requirements for related party transactions within the company. It references relevant laws and stock exchange rules, and is issued by the company's board. The document is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and procedures for managing related party transactions, which falls under governance information. The document length is 7363 characters, indicating it is a full policy document rather than a brief announcement or notice.
2025-10-28 Chinese
对外担保管理制度(2025年10月）
Governance Information Classification · 95% confidence The document is titled '对外担保管理制度' which translates to 'External Guarantee Management System' and contains detailed internal rules and procedures regarding the company's external guarantees, including approval processes, risk management, responsibilities, and disclosure obligations. It is a governance-related internal policy document rather than a financial report, announcement, or regulatory filing. There is no indication of financial statements, audit results, earnings data, or meeting materials. The document is a formal internal governance policy established by the board and approved by shareholders, focusing on the company's governance practices related to external guarantees. Therefore, the most appropriate classification is Governance Information (CGR).
2025-10-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.